Original · pages 81–83
The EndoBarrier as a Novel Minimally Invasive Treatment of Type 2 Diabetes and Obesity: A Literature Review and Case Series of over 50 patients
Cite this article
David N. Hakim, ShaneelPatel, Sandra ElDoueihy, Nadey S. Hakim. The EndoBarrier as a Novel Minimally Invasive Treatment of Type 2 Diabetes and Obesity: A Literature Review and Case Series of over 50 patients. J Int Med Sci Acad. 2016;29(2):81–83.
Opening of the article
Surgical intervention is now the most effective treatment for patients with type 2 diabetes (T2DM) and severe obesity. There is currently a lack of minimally invasive technology to effectively treat obesity and T2DM. The Duodenal–jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) is an endoscopically inserted device that aids weight loss and immediately improves glycaemia through neurological and endocrine mechanisms.Firstly, we conducted a review of articles published on MEDLINE involving more than 300 patients to ascertain metabolic outcomes and safety profiles of the EndoBarrier.